The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Product | 5,420 |
| License And Service | 2,276 |
| Revenue | 7,696 |
| Cost of product revenue | 1,076 |
| Paltusotine | 68,337 |
| Atumelnant | 48,131 |
| Other research and development programs | 33,322 |
| Research and development personnel expenses | 102,677 |
| Research and development stock-based compensation | 50,344 |
| Other research and development | 29,247 |
| Total research and development expenses | 332,058 |
| External selling, general and administrative expenses | 90,013 |
| Selling, general and administrative personnel expenses | 60,638 |
| Selling, general and administrative stock-based compensation | 40,680 |
| Selling, general and administrative | 191,331 |
| Total other income, net | 51,632 |
| Income tax expense | 180 |
| Loss on equity method investment | 0 |
| Net loss | -465,317 |
| Stock-based compensation | 91,024 |
| Depreciation and amortization | 3,890 |
| Noncash lease expense | 3,014 |
| Accretion of purchase discounts and amortization of premiums on investment securities, net | 15,425 |
| Loss on equity method investment | 0 |
| Loss on disposal of property and equipment | -50 |
| Trade accounts receivable | 592 |
| Inventory | 2,022 |
| Prepaid expenses and other assets | 16,511 |
| Accounts payable and accrued expenses, compensation and related expenses, and other non-current liabilities | 28,983 |
| Deferred revenue | -1,835 |
| Operating lease liabilities | -3,181 |
| Net cash used in operating activities | -377,922 |
| Purchases of investment securities | 1,004,427 |
| Purchase of radionetics preferred stock | 0 |
| Maturities and sale of investment securities | 1,184,097 |
| Purchases of property and equipment | 5,762 |
| Net cash provided by (used in) investing activities | 173,908 |
| Proceeds from issuance of common stock, net of commissions | 0 |
| Offering costs related to issuance of common stock | 0 |
| Proceeds from exercise of stock options and shares issued under employee stock purchase plan | 40,611 |
| Net cash provided by financing activities | 40,611 |
| Net change in cash, cash equivalents and restricted cash | -163,403 |
| Exchange rate changes on cash, cash equivalents and restricted cash | -106 |
| Cash, cash equivalents and restricted cash - beginning of period | 265,845 |
| Cash, cash equivalents and restricted cash - end of period | 102,336 |
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)